Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human CDKN2B Anticorps:
anti-Mouse (Murine) CDKN2B Anticorps:
anti-Rat (Rattus) CDKN2B Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal CDKN2B Primary Antibody pour ICC, IF - ABIN407770
Siddiqi, Terry, Matushansky: Hiwi mediated tumorigenesis is associated with DNA hypermethylation. dans PLoS ONE 2012
Human Polyclonal CDKN2B Primary Antibody pour ELISA, WB - ABIN560313
Ratovitski: Phospho-?Np63?-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death. dans FEBS letters 2013
Human Polyclonal CDKN2B Primary Antibody pour ELISA, WB - ABIN4342269
Geyer: Strategies to re-express epigenetically silenced p15(INK4b) and p21(WAF1) genes in acute myeloid leukemia. dans Epigenetics 2010
Among 8 SNPs in 3 loci that showed at least nominal association (P < 5.00E-02) in the primary cohort, a representative SNP for each loci (rs2157719 for CDKN2B-AS1 (Montrer PTGDR Anticorps), rs33912345 for SIX6 (Montrer SIX6 Anticorps), and rs9913911 for GAS7 (Montrer GAS7 Anticorps)) were selected
The role of CDKN2A (Montrer CDKN2A Anticorps)/B deletions in pediatric acute lymphoblastic leukemia
The summary of evidences suggesting that RD(INK4/ARF (Montrer CDKN2A Anticorps)) enhancer deletion represents a novel mutation in the INK4-ARF (Montrer CDKN2A Anticorps) locus independent of well-known p15, p16 (Montrer CDKN2A Anticorps), p14ARF (Montrer CDKN2A Anticorps) alterations.
Results show that expression of CDKN2B was reduced significantly in colorectal cancer (CRC (Montrer CALR Anticorps)) and its promotor is targeted by miR (Montrer MLXIP Anticorps)-18b which controls its regulation.
Mechanistic investigations demonstrated that BLACAT1 had a key role in G1/G0 arrest, and showed that BLACAT1 can repress p15 expression by binding to EZH2 (Montrer EZH2 Anticorps), thus contributing to the regulation of CRC (Montrer CALR Anticorps) cell cycle and proliferation. Our results suggest that BLACAT1, as a cell cycle regulator (Montrer CDKN2A Anticorps), may serve as a potential target for colon cancer prevention and treatment in human CRC (Montrer CALR Anticorps)
The current study supports a relevant role for p15, p16 (Montrer CDKN2A Anticorps), and DAPK (Montrer DAPK1 Anticorps) hypermethylation in the genesis of the plasma cell neoplasm. DAPK (Montrer DAPK1 Anticorps) hypermethylation also might be an important step in the progression from MGUS to MM.
DNA methylation (Montrer HELLS Anticorps) of CDKN2B may play a potential role in artery calcification.
These data support the hypothesis that decreased p15 expression is a robust biomarker for distinguishing nevus from melanoma.
Here we present, as far as we are aware, the first case of metastatic microcystic adnexal carcinoma with DNA sequencing results indicating a mutation in TP53 (Montrer TP53 Anticorps) and chromosomal losses in cyclin dependent kinase inhibitor 2A (CDKN2A (Montrer CDKN2A Anticorps)) and cyclin dependent kinase inhibitor 2B (CDKN2B).
results provide evidence for the influence of genetic variants at CDKN2A (Montrer CDKN2A Anticorps)/B locus with the risk of developing B-AL
miR (Montrer MLXIP Anticorps)-541 contributes to microcystin-LR-induced testicular toxicity by regulating the expression of p15 and promoting apoptosis.
The expression of three tumor suppressor genes encoded in the INK4/ARF (Montrer CDKN2A Anticorps) locus (p15(INK4b), p16(INK4a (Montrer CDKN2A Anticorps)), and p19(ARF (Montrer CDKN2A Anticorps))) was decreased in E6AP (Montrer ube3a Anticorps)(-/-) embryo fibroblasts.
Data show that the Wnt (Montrer WNT2 Anticorps)-effector hepatocyte nuclear factor 1-alpha (Tcf1 (Montrer HNF1A Anticorps)) is recruited to and triggers transcription of the Ink4/Arf (Montrer CDKN2A Anticorps) tumor suppressor locus, such as as p15Ink4b, p16Ink4a (Montrer CDKN2A Anticorps) and p19Arf (Montrer CDKN2A Anticorps).
Loss of Nf2 (Montrer NF2 Anticorps) and Cdkn2a (Montrer CDKN2A Anticorps)/b have synergistic effects with PDGF-B (Montrer PDGFB Anticorps) overexpression promoting meningioma malignant transformation.
Loss of CDKN2B may not only promote cardiovascular disease through the development of atherosclerosis but may also impair TGFbeta (Montrer TGFB1 Anticorps) signaling and hypoxic neovessel maturation.
Control of CD8 (Montrer CD8A Anticorps) T cell proliferation and terminal differentiation by active STAT5 (Montrer STAT5A Anticorps) and CDKN2A/CDKN2B.
Radiation-induced double strand breaks cooperate with loss of Ink4 (Montrer CDKN2A Anticorps) and Arf (Montrer CDKN2A Anticorps) tumor suppressors to generate high-grade gliomas that are commonly driven by Met amplification and activation.
When overexpressed in naked mole rat or human cells, pALT(INK4a (Montrer CDKN2A Anticorps)/b) has stronger ability to induce cell-cycle arrest than either p15(INK4b) or p16(INK4a (Montrer CDKN2A Anticorps)).
Cdk4 (Montrer CDK4 Anticorps) and Cdk6 (Montrer CDK6 Anticorps) cooperate in hematopoietic tumor development and suggest a role for Cdk6 (Montrer CDK6 Anticorps) in sequestering INK4 (Montrer CDKN2A Anticorps) proteins away from Cdk4 (Montrer CDK4 Anticorps).
Data indicate that loss of cyclin-dependent kinase inhibitor p15 (p15Ink4b) collaborates with oncogene (Montrer RAB1A Anticorps) fusion protein Nup98 (Montrer NUP98 Anticorps)-HoxD13 (Montrer HOXD13 Anticorps) transgene in the development of predominantly myeloid neoplasms.
This gene lies adjacent to the tumor suppressor gene CDKN2A in a region that is frequently mutated and deleted in a wide variety of tumors. This gene encodes a cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or CDK6, and prevents the activation of the CDK kinases, thus the encoded protein functions as a cell growth regulator that controls cell cycle G1 progression. The expression of this gene was found to be dramatically induced by TGF beta, which suggested its role in the TGF beta induced growth inhibition. Two alternatively spliced transcript variants of this gene, which encode distinct proteins, have been reported.
Cyclin-dependent kinase 4 inhibitor B
, CDK inhibitory protein
, CDK4B inhibitor
, cyclin-dependent kinase 4 inhibitor B
, cyclin-dependent kinases 4 and 6 binding protein
, multiple tumor suppressor 2
, p14_CDK inhibitor
, p15 CDK inhibitor
, cyclin-dependent kinase inhibitor p15
, cyclin-dependent kinase inhibitor p15INK4b
, cyclin-dependent kinase inhibitor protein
, Cyclin dependent kinase inhibitor 2B (p15, inhibits CDK4)
, cyclin dependant kinase inhibitor
, cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)
, cyclin-dependent kinase inhibitor 2B
, cyclin-dependent kinase inhibitor 2B (melanoma, p16, inhibits CDK4)
, p15INK4b tumor suppressor